NUSSG-01 study

ABSTRACT: Interventions: Patients in the synbiotics group intake Super Synbiotics LBG-P while they are waiting for surgery. LBG-P consists of Probiotics packets and Prebiotics packets and patients intake each packet 3 times per day. Patients in the non-synbiotics group do not take LBG-P. Patients are prohibited to intake other synbiotics during the study period. Primary outcome(s): The effects of synbiotics administration on the tumor microenvironment of colorectal cancer (metastatic lesions will also be analyzed if they are simultaneously resected with primary lesion). In detail, the expressions of immune response factors (including PD-L1 expression, counts of intraepithelial lymphocytes), inflammation-associated factors, anti-tumor factors, and tumor proliferation factors will be determined by the immunohistochemistry between synbiotics and non-synbiotics group. Study Design: randomized controlled trial, open(masking not used), no treatment control/standard of care control, crossover assignment, treatment purpose

DISEASE(S): Colorectal Cancer

PROVIDER: 2615044 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR